Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016-2017 by Vu, T.V.D. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-04 and may be subject to
change.
Vu et al. Antimicrob Resist Infect Control           (2021) 10:78  
https://doi.org/10.1186/s13756-021-00937-4
RESEARCH
Antimicrobial susceptibility testing results 
from 13 hospitals in Viet Nam: VINARES 2016–
2017
Tien Viet Dung Vu1* , Marc Choisy1,3, Thi Thuy Nga Do1, Van Minh Hoang Nguyen1, James I. Campbell1, 
Thi Hoi Le2, Vu Trung Nguyen2, Heiman F. L. Wertheim1,4, Ngoc Thach Pham2, Van Kinh Nguyen2 and 
H. Rogier van Doorn1,3the VINARES consortium 
Abstract 
Objective: To analyse data from 2016–17 from a hospital-based antimicrobial resistance surveillance with national 
coverage in a network of hospitals Viet Nam.
Methods: We analysed data from 13 hospitals, 3 less than the dataset from the 2012–13 period. Identification and 
antimicrobial susceptibility testing data from the clinical microbiology laboratories from samples sent in for routine 
diagnostics were used. Clinical and Laboratory Standards Institute 2018 guidelines were used for antimicrobial sus-
ceptibility testing interpretation. WHONET was used for data entry, management and analysis.
Results: 42,553 deduplicated isolates were included in this analysis; including 30,222 (71%) Gram-negative and 
12,331 (29%) Gram-positive bacteria. 8,793 (21%) were from ICUs and 7,439 (18%) isolates were from invasive infec-
tions. Escherichia coli and Staphylococcus aureus were the most frequently detected species with 9,092 (21%) and 
4,833 isolates (11%), respectively; followed by Klebsiella pneumoniae (3,858 isolates – 9.1%) and Acinetobacter bau-
mannii (3,870 isolates – 9%). Bacteria were mainly isolated from sputum (8,798 isolates – 21%), blood (7,118 isolates 
– 17%) and urine (5,202 isolates – 12%). Among Gram-positives 3,302/4,515 isolates (73%) of S. aureus were MRSA; 
99/290 (34%) of Enterococcus faecium were resistant to vancomycin; and 58% (663/1,136) of Streptococcus pneumoniae 
proportion were reduced susceptible to penicillin. Among Gram-negatives 59% (4,085/6,953) and 40% (1,186/2,958) 
of E. coli and K. pneumoniae produced ESBL and 29% (376/1,298) and 11% (961/8,830) were resistant to carbapenems, 
respectively. 79% (2855/3622) and 45% (1,514/3,376) of Acinetobacter spp. and Pseudomonas aeruginosa were carbap-
enem resistant, respectively. 88% (804/911) of Haemophilus influenzae were ampicillin resistant and 18/253 (7%) of 
Salmonella spp. and 7/46 (15%) of Shigella spp. were resistant to fluoroquinolones. The number of isolates from which 
data were submitted in the 2016–2017 period was twice as high as in 2012–2013. AMR proportions were higher in 
2016–2017 for most pathogen-antimicrobial combinations of interest including imipenem-resistant A. baumannii, P. 
aeruginosa and Enterobacterales.
Conclusions: The data show alarmingly high and increasing resistant proportions among important organisms in 
Viet Nam. AMR proportions varied across hospital types and should be interpreted with caution because existing sam-
pling bias and missing information on whether isolates were community or hospital acquired. Affordable and scalable 
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Introduction
In a 2015 estimate based on data from the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net), over 33,000 (out of 445 million inhabitants) peo-
ple die each year in the European Union as a direct 
consequence of drug resistant infections [1]. Data from 
low- and middle-income countries (LMICs) are rare, 
but a recent paper from Thailand – with a population 
of 69 million – estimated that 19,122 of 45,209 (43%) 
deaths in patients with hospital-acquired infections are 
due to drug resistant infections. This higher number of 
deaths per capita attributable to AMR in Thailand in 
comparison with the EU suggests the burden of AMR 
in LMICs may be higher [2].
In their 2014 review, Rossolini et al. indicated an out-
of-control crisis for Gram-negative pathogens, par-
ticularly with the worrisome emergence and spread of 
carbapenem-resistant Enterobacterales, especially in 
the hospital environment, while Gram-positive patho-
gens appear to be relatively under control [3].
In May 2015, the World Health Assembly adopted a 
Global Action Plan on Antimicrobial Resistance, which 
highlighted the need to improve awareness and under-
standing of antimicrobial resistance and to strengthen 
the knowledge and evidence-based decisions through 
surveillance and research [4]. The review by the World 
Health Organisation (WHO) pointed out the lack of a 
global consensus on methodology and data collection 
for AMR surveillance. In addition, routine surveillance 
often uses samples from severe cases including those 
with hospital acquired infections and those with treat-
ment failure, leading to an under-representation of 
samples from patients with community-acquired infec-
tions (CAI) and failure of the data to properly inform 
treatment guidelines [5]. As a response to this situation, 
WHO introduced that same year the Global Antimicro-
bial Resistance Surveillance System (GLASS). GLASS 
aims to enable standardized, comparable and validated 
AMR data collection and analysis and sharing of AMR 
data across countries to inform decision-making and 
action [6].
AMR surveillance activities were initiated in Viet 
Nam in 1988 with specific programs as summarised 
previously [7], including VINARES, a network of 16 
hospitals throughout the country collecting data on 
antimicrobial consumption and resistance and hospi-
tal-acquired infections [7]-[10].
These projects highlighted the high proportions of 
resistance among several WHO GLASS target pathogens: 
carbapenem-resistant Acinetobacter baumannii (40% 
in the Global Antibiotic Resistance Partnership (GARP) 
in 2009 [11] and 70% in VINARES in 2012 [7]); Escheri-
chia coli and Klebsiella pneumoniae producing extended 
spectrum beta-lactamase (ESBL) (30% and 43% in 2009, 
respectively); carbapenem-resistant E. coli (2% in 2009 
[11] and 6% in 2012 [7]); carbapenem-resistant K. pneu-
moniae (10% in 2009 [11] and 17% in 2012 [7]); methi-
cillin-resistant Staphylococcus aureus (MRSA), reported 
at 30.1% among hospital-acquired infections in 2004 [12] 
and at 69% among all isolates 2012 [7].
In 2013, the Viet Nam Ministry of Health published 
its national action plan on AMR, including strengthen-
ing and improving the national surveillance system on 
the use of antimicrobials and drug resistance [13]. In 
2015, Viet Nam received pilot funding from the Fleming 
Fund to establish a National AMR surveillance network 
and reference laboratory [10]. The VINARES network 
was recognised in 2016 by the Ministry of Health as the 
national AMR surveillance network and continues to 
receive support from the Fleming Fund as part of the 
country grant for Viet Nam led by FHI360. The national 
AMR surveillance network also receives support from 
the US Centers for Disease Control and Prevention 
(US CDC) and Program for Appropriate Technology 
in Health (PATH) as part of the Global Health Security 
Agenda. A surveillance protocol based on GLASS and 
the Fleming Fund roadmap is being developed by the 
Ministry of Health with support from US CDC, WHO 
and Oxford University Clinical Research Unit (OUCRU). 
Data collection as part of a project on development on 
evidence based guidelines restarted in 2016 [10].
Here, we present the identification and antimicrobial 
susceptibility testing (AST) results from isolates from 
clinical specimens from 13 microbiology laboratories 
participating in VINARES between June 2016 and May 
2017. These results provide an insight in the dynamics 
of AMR and an update on the earlier results published 




The VINARES network was described previously [7, 8]. 
In 2016–2017, 13 hospitals (7 provincial, 3 specialised 
ways to adopt a sample- or case-based approach across the network should be explored and clinical data should be 
integrated to help provide more accurate inferences of the surveillance data.
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and 3 national) continued to participate in the network, 
among which 4 were in the northern, 5 in the central and 
4 in the southern region of Viet Nam; there were 1 paedi-
atric and 2 infectious diseases hospitals (Fig. 1).
Thirteen hospitals submitted their routine identi-
fication and AST results quarterly by email from May 
2016 to April 2017. These were results from all bacte-
rial isolates from clinical specimens sent in for routine 
diagnostics at the microbiology lab of the hospitals. 
WHONET was used for data entry, management and 
analysis [14]. Routine AST data at the participating 
laboratories was entered into WHONET 5.6 by hospital 
technicians or was exported from automated systems 
including VITEK2 (bioMérieux, Marcy l’Etoile, France) 
or Phoenix automated microbiology system (BD Diag-
nostic Systems, Sparks, MD, USA) using LABCONN 
(LabSoft, Viet Nam). Raw data files were extracted and 
submitted by email. Files were converted to WHONET 
format using BacLink, a free tool included in WHONET 
[15]. All data files were combined into a single file. Data 
files were checked for common errors and compatibil-
ity (language and file structure). Sites had received reg-
ular training from OUCRU and National Hospital for 
Tropical Diseases staff since 2012, were enrolled into 
an external quality assurance scheme (UK-NEQAS) and 
received Vietnamese translated Clinical and Laboratory 
Standards Institute (CLSI) guidelines.
AST results were obtained by disk diffusion (DD) and 
minimum inhibitory concentration (MIC) methods. 
The proportion of MIC testing depended on the labo-
ratory, the specific pathogen-antimicrobial combina-
tion and the period of study as detailed in Additional 
file 1:  table S1. AST results were categorised according 
to the CLSI 2018 guidelines as susceptible, intermedi-
ate, resistant or unknown. For each pathogen and anti-
microbial under surveillance, the proportion of patients 
with growth of resistant bacteria was calculated in all 
specimens, and separately in specimens from Intensive 
Care Units (ICU), invasive infection (blood and cer-
ebrospinal fluid (CSF)) or stool (for Shigella spp. and 
Salmonella spp.). AST results were interpreted using 
WHONET (version 5.6) and then summarized in R 
software [16].
MRSA was assessed using oxacillin and cefoxitin 
screening. As not all hospitals used molecular or other 
confirmation testing, an S. aureus isolate was considered 
MRSA if it was resistant to one of these two antimicro-
bials. In 2012–13, reduced susceptibility to penicillin in 
Streptococcus pneumoniae was mostly detected using 
oxacillin screening [7]. In 2016–17 this was more com-
monly done directly by penicillin susceptibility testing 
using both disk diffusion and MIC by E-test or auto-
mated systems. Oxacillin susceptibility results were used 
in case of missing penicillin susceptibility testing results.
We included five antibiotic classes: carbapenems (imi-
penem, meropenem and ertapenem), aminoglycosides 
(amikacin, gentamicin and tobramycin), fluoroqui-
nolones (ciprofloxacine and levofloxacine), macrolides 
(azithromycin, erythromycin and clindamycin) and ceph-
alosporins (ceftriaxone and cefepime).
Multidrug Resistant (MDR) and Extensively drug 
resistant (XDR) E. coli, K. pneumoniae, Pseudomonas 
aeruginosa, A. baumannii and S. aureus were defined as 
follows:
• E. coli and K. pneumoniae MDR: non-CRE and 
resistant to one third-generation cephalosporin, cip-
rofloxacin and one aminoglycoside.
• E. coli and K. pneumoniae XDR: carbapenem resist-
ant and resistant to one third-generation cephalo-
sporin, ciprofloxacin and one aminoglycoside.
• P. aeruginosa MDR: resistant to three of the following 
four antibiotics: imipenem, ceftazidime, ciprofloxa-
cin and tobramycin [17].
• A. baumannii MDR: resistant to at least one agent in 
three of the following four antibiotic classes: carbap-
Fig. 1 Fig. 1 Location, speciality, and type of the 13 participating 
hospitals in the VINARES 2016–2017 project
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enems, aminoglycosides, fluoroquinolones and ceph-
alosporins [18].
• S. aureus MDR: MRSA.
Statistical analysis
We analysed data for eleven pathogens: A. baumannii, 
P. aeruginosa, E. coli, K. pneumoniae, Enterobacter spp., 
Enterococcus faecium, S. aureus, S. pneumoniae, Haemo-
philus influenzae, Salmonella spp. and Shigella spp. [19]. 
Data were de-duplicated, so that one isolate represents 
one patient. Only the first isolate per patient, per path-
ogen, per reporting period, per stratification level (hos-
pital) was included. This also minimized bias associated 
with reporting of repeat cultures [20]. Local specimen 
types were converted into specimen types compatible 
with WHONET.
An analysis of antibiotic resistance by hospital type 
was carried out. Three hospital types were considered: 
national and provincial level general and specialised hos-
pitals, as shown in Fig.  1. Among the 16 hospitals par-
ticipating in VINARES 2012–2013, three (one national 
and two specialised, all in the northern region) did not 
participate in 2016–2017 period. Data from each hospi-
tal type were pooled and analysed. This analysis served 
to compare susceptibility between hospital types. Only 
the pathogen-antimicrobial combinations with the high-
est sample numbers were selected, including imipenem-
resistant A. baumannii, E. coli, ESBL-producing E. coli 
and MRSA.
Resistant proportions of pathogen-antimicrobial com-
binations between two periods of VINARES were com-
pared using Chi-square test (significance level = 0.05).
Results
Distribution of bacteria and antibiotics
Between May 2016 and April 2017, hospitals submit-
ted results from 75,051 specimens. Among them, 22,752 
records were unknown or reported no growth, 48,084 
were from Gram-negative and Gram-positive bacteria, 
882 were fungi, 1454 were anaerobes, 1,864 were myco-
bacteria and 15 were parasites.
After removal of negative cultures, fungi, anaerobes, 
mycobacteria and parasites and deduplication, results 
from 42,553 isolates were included in the analysis; 
including from 30,222 (71%) Gram-negative and 12,331 
(29%) Gram-positive bacteria. Among all isolates, 8,793 
(21%) were from ICUs and 7,439 (18%) were from inva-
sive infections.
E. coli and S. aureus were the most frequently iso-
lated species with 9,092 (21%) and 4,833 isolates (11%), 
respectively; followed by K. pneumoniae (3,870 isolates 
– 9%) and A. baumannii (3,710 isolates – 9%). Bacteria 
were mainly isolated from sputum (8,798 isolates – 21%), 
blood (7,118 isolates – 17%) and urine (5,202 isolates 
– 12%); 321 isolates (1%) were from cerebrospinal fluid 
(CSF).
AST results were obtained by disk diffusion (DD) and 
MIC methods. Details by laboratory, period, and bacte-
ria-drug combination are described in Table S1. Two lab-
oratories used 100% DD in the first period and 100% MIC 
in the second period, one laboratory used MIC in the first 
period and DD in second period, and others kept 100% 
DD for MRSA screening in both periods. Among the 13 
hospitals participating in the two periods, the number of 
hospitals that used MIC for ESBL testing increased from 
6 to 12. As a result, we observed an increase in the num-
ber of ESBL-producing E. coli and K. pneumoniae tests 
(1659 in the first period and 9911 in the second period). 
This increase might also be because more hospitals 
switched from manual to automated systems, and ESBL 
were tested for all samples and not just to confirm third-
generation cephalosporins resistance. Two laboratories 
in the  2nd period of VINARES used MIC for imipenem-
resistance testing versus only one in the  1st period. Pen-
icillin-susceptibility of S. pneumoniae were tested using 
MIC by three laboratories with 86/344 (25%) tests in the 
 1st period, while they were tested using MIC in six labo-
ratories with 694/1,136 (61%) tests in the  2nd period.
Antibiotic susceptibility testing results of Gram‑positive 
bacteria
Antimicrobial susceptibility testing results of bacteria 
from all specimens and from invasive infections or stool 
are shown in Tables  1, 2, 3, 4, respectively. Additional 
file 1: Table 2a and 2b shows AST results from ICUs.
Since not all isolates were tested for all listed antibi-
otics, the denominator of each susceptible proportion 
test was different and smaller than the total number of 
isolates collected. There were 4,833 S. aureus isolates, 
including 715 (15%) from blood and CSF. 690 isolates 
(14%) were from ICU. 73% (3,302/4,515 isolates) of S. 
aureus were MRSA, 71% of S. aureus (476/674) from 
blood and CSF were MRSA. Among the isolates from 
ICU, the proportion of MRSA was 75% (478/640). The 
proportion reported as non-susceptible to vancomycin 
was low (2% (45/2,680) in all specimens and 1% (7/565) in 
blood and CSF). No confirmatory testing for vancomycin 
resistance was reported. The proportion resistant to mac-
rolides was 83% (38,61/4,661) in all specimens.
E. faecium was isolated from 296 specimens; among 
which 51 (17%) were blood and CSF and 65 (22%) were 
from ICU. 34/46 tested isolates (74%) were high level 
aminoglycoside-resistant, 7/9 isolated from blood and 
CSF. 99/290 isolates (34%) of E. faecium were resistant to 
vancomycin (VRE) (19% of VRE tests were done by MIC 
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Table 1 Antimicrobial susceptibility testing results of three gram-positive bacteria in all specimens of 13 hospitals in VINARES 
2016–2017 project. Denominators and numerators are the numbers of tested resistant isolates respectively. Corresponding resistant 
percentages are in brackets
SXT: Trimethoprim/Sulfamethoxazole
S. aureus (N = 4833) S. pneumoniae (N = 1367) E. faecium (N = 296)
Aminoglycosides 1674/4090 (41%) 34/46 (74%)
Fluoroquinolones 1720/4618 (37%) 31/1117 (3%)
Macrolides 3861/4661 (83%) 1234/1317 (94%) 249/262 (95%)
Penicillin 2347/2400 (98%) 663/1136 (58%) 111/124 (90%)
SXT 1021/4158 (25%) 886/1069 (83%) 73/77 (95%)
Ampicillin 57/64 (89%) 2/21 (10%) 228/253 (90%)
Vancomycin 45/2680 (2%)* 16/1229 (1%) 91/290 (31%)
Table 2 Antimicrobial susceptibility testing results of eight gram-negative bacteria in all specimens of 13 hospitals in VINARES 2016–
2017 project. Denominators and numerators are the numbers of tested and resistant isolates respectively. Corresponding resistant 
percentages are in brackets
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Table 3 Antimicrobial susceptibility testing results in blood and CSF of three gram-positive bacteria of 13 hospitals in VINARES 2016–
2017 project. Denominators and numerators are the numbers of tested and resistant isolates respectively. Corresponding resistant 
percentages are in brackets
SXT: Trimethoprim/Sulfamethoxazole
S. aureus (N = 715) S. pneumoniae (N = 160) E. faecium (N = 51)
Aminoglycosides 294/637 (46%) 7/9 (78%)
Fluoroquinolones 297/689 (43%) 2/143 (1%)
Macrolides 545/693 (79%) 140/152 (92%) 46/48 (96%)
Penicillin 490/504 (97%) 42/114 (37%) 19/22 (86%)
SXT 233/661 (35%) 107/134 (80%) 20/20 (100%)
Ampicillin 37/40 (92%)
Vancomycin 7/565 (1%)* 4/148 (3%) 13/51 (25%)
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method). 22 of 64 isolates (36%) from ICU were reported 
as vancomycin-resistant.
1,367 S. pneumoniae were isolated among which 160 
(12%) were from blood and CSF and 184 isolates (13%) 
were from ICU. The penicillin-resistant S. pneumoniae 
proportion was 58% (663/1,136) in all specimens, and 
lower in blood and CSF (37%, 42/114 isolates) and among 
isolates from specimens collected in ICU (29%, 42/146 
isolates). 691/794 (87%) of penicillin susceptibility tests 
were done by MIC method. 58/356 (16%) S. pneumoniae 
isolates were cephalosporin-resistant; this proportion 
was lower among ICU isolates (11%, 10/94). Two isolates 
(0.2%) were recorded as resistant to vancomycin, none of 
them were from blood/CSF or ICU.
Antibiotic susceptibility testing results of Gram‑negative 
bacteria
The numbers of K. pneumoniae, E.  coli and Enterobac-
ter spp. were 3,870, 9,092 and 1,322, respectively. In 
blood and CSF, these proportions were 12% (482/3,870), 
17% (1,535/9,092) and 6% (77/1,322) in same order. The 
proportions of K. pneumoniae, E. coli and Enterobac-
ter spp. isolated from ICUs were 28% (1,069/3,870), 
11% (1,016/9,092 isolates) and 17% (230/1,322), respec-
tively. The proportion of E. coli carrying ESBL was 59% 
(4,085/6,953) and 40% (1,186/2,958) in K. pneumo-
niae. Carbapenem-resistance among K. pneumoniae, 
E. coli and Enterobacter spp. was 29% (376/1,298), 11% 
(961/8,830) and 27% (1,049/3,816), respectively. Tri-
methoprim/sulfamethoxazole-resistance ranged from 
47% (215/454) of K. pneumoniae in blood and CSF to 
76% (700/925) of E. coli in ICU. MDR proportions of E. 
coli and K. pneumoniae were 29% (2,015/6,956) and 14% 
(428/3,141), respectively. There were 514/6,956 (7%) of E. 
coli and 722/3,141 (23%) of K. pneumoniae classified as 
XDR.
The number of isolates of A. baumannii and P. aer-
uginosa were similar (3,710 and 3,461, respectively). 187 
(5%) isolates of A. baumannii and 482 (13%) of P. aer-
uginosa were isolated from blood and CSF. A high pro-
portion of A. baumannii and P. aeruginosa isolates were 
from ICU (32% (1,176/3,710) and 33% (1,158/3,461), 
respectively). Ceftazidime-resistant proportions of A. 
baumannii in all specimens and in ICU were 2,743/3,298 
(83%) and 866/958 (90%). These resistant proportions 
in P. aeruginosa were 1,378/3,231 (43%) and 574/1,062 
(54%). Carbapenem-resistant proportions of A. bauman-
nii and P. aeruginosa were 79% (2,855/3,622) and 45% 
(1,514/3,376), respectively. Out of 1,566 P. aeruginosa 
tested with the four selected antibiotics, 660 isolates 
(42%) were MDR. 2,781/3,442 (81%) of the tested A. bau-
mannii isolates were MDR.
Of 1,085 H. influenzae isolates submitted, 146 were 
from ICU and 12 were from blood and CSF. The pro-
portion of ampicillin-resistant H. influenzae was 88% 
(804/911) among all isolates; this proportion was higher 
among isolates collected on ICU (92/98 isolates – 94%). 
Three percent (18/664) of H. influenzae isolates were 
cephalosporins-resistant, while none were found resist-
ant to carbapenems.
Salmonella spp. and Shigella spp. susceptibility were 
investigated in all specimens and in stool. Among 277 iso-
lates of Salmonella spp., there were 32 isolates from stool 
and 18 isolates from ICU. Fluoroquinolones-resistant 
Table 4 Antimicrobial susceptibility testing results in blood and CSF of A. baumannii, P. aeruginosa, E. coli, K. pneumoniae, Enterobacter 
spp., E. faecium, S. aureus, S. pneumoniae and H. influenzae; in stool for Salmonella spp. and Shigella spp. of 13 hospitals in VINARES 2016–
2017 project. Denominators and numerators are the numbers of tested and resistant isolates respectively. Corresponding resistant 
percentages are in brackets



















Carbapenem 116/1483 (8%) 109/476 (23%) 110/183 (60%) 54/139 (39%) 20/77 (26%) 1/14 (7%) 0/19 (0%) 0/11 (0%)
Aminoglyco-
sides
637/1471 (43%) 195/470 (41%) 107/185 (58%) 48/138 (35%) 35/75 (47%)
Fluoroquinolo-
nes
953/1475 (65%) 177/459 (39%) 96/182 (53%) 37/138 (27%) 24/76 (32%) 4/31 (13%) 3/27 (11%) 0/9 (0%)
Cephalosporins 931/1402 (66%) 221/471 (47%) 118/178 (66%) 47/120 (39%) 37/66 (56%) 7/21 (33%) 4/28 (14%) 0/11 (0%)
Macrolides 1/1 (100%) 2/3 (67%) 1/5 (20%) 0/4 (0%)
SXT 935/1377 (68%) 215/454 (47%) 74/82 (90%) 29/57 (51%) 31/34 (91%) 6/30 (20%) 5/8 (62%)
AMC 180/577 (31%) 112/285 (39%) 26/32 (81%) 1/5 (20%)
Ampicillin 928/1028 (90%) 278/287 (97%) 21/23 (91%) 23/33 (70%) 14/31 (45%) 7/8 (88%)
TCC 169/356 (47%) 115/195 (59%) 46/110 (42%) 14/45 (31%)
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Salmonella spp. in all specimens and in stool were 7% 
(18/253 and 11% (3/27), respectively. Among 53 Shigella 
spp. isolates, 70% came from stool. 7/46 (15%) of Shigella 
spp. were fluoroquinolones-resistant.
Susceptibility by hospital type
Carbapenem-resistant A. baumannii, ESBL positive E. 
coli and MRSA in national, provincial general and spe-
cialised hospitals were compared, as the number of these 
pathogen-antimicrobial combinations were high enough 
for reliable comparison. Details are shown in Additional 
file  1: Table  3. A. baumannii had the highest carbape-
nem resistant proportion in national level hospitals, fol-
lowed by specialised and provincial level hospitals (82% 
(1,979/2,413), 77% (444/577) and 68% (432/632), respec-
tively). E. coli showed a different ESBL positive propor-
tion between national and provincial level hospitals (58% 
(2,145/3,726) and 65% (1,541/2,371), respectively). MRSA 
proportions were lower in provincial (71% (1,499/2,115)) 
and specialised hospitals (72% (688/960)) than in national 
level hospitals (77% (1,115/1,440)).
Comparison with data from VINARES 2012–2013
We compared the susceptibility of bacteria-antimicro-
bial combinations between the two periods of VINARES 
(2012–2013 versus 2016–2017). Laboratories used simi-
lar protocols in the two periods, including antimicro-
bial susceptibility testing methods using translated CLSI 
guidelines and data collection procedures. Laboratories 
were enrolled in the UK-NEQAS external quality assess-
ment programme during both data collection periods. 
Since the VINARES 2016–2017 had 13 hospitals, we 
calculated the antimicrobial susceptibility result of VIN-
ARES 2012–2013 in whole dataset and in a subset of 13 
hospitals. Table 5 shows resistant proportions of priority 
pathogen-antimicrobial combinations between the two 
periods.
The total number of isolates submitted in the 2016–
2017 period was twice as high as in the 2012–2013 
period; for some pathogen-antimicrobial combinations 
the number of isolates was up to fourfold (eg. fourfold 
for in ESBL, threefold for MRSA). Overall, antimicro-
bial resistant proportions were higher in 2016–2017 
for almost all pathogen-antimicrobial combinations of 
Table 5 Resistance proportion of priority bacteria-antimicrobial combinations in all specimens and in blood and CSF, in 2012 
and 2016. Denominators and numerators are the numbers of tested and resistant isolates respectively. Corresponding resistant 
percentages are in brackets
ESBL: extended-spectrum β-lactamase; *: Intermediate and Resistant; **: Combination result of oxacillin screening and penicillin MIC test; MDR: Multi-drug resistant; 
XDR: Extensively drug resistant; MRSA: Methicillin-resistant Staphylococcus aureus











ESBL E. coli 1337/1928 (69%) 626/844 (74%) 4085/6953 (59%) 126/183 (69%) 59/81 (73%) 655/1107 (59%)
Imipenem E. coli 180/2 977 (6%) 145/2111 (7%) 687/8438 (8%) 15/403 (4%) 9/309 (3%) 92/1410 (7%)
Ceftriaxone E. coli 2342/4 192 (56%) 776/1472 (53%) 5051/7049 (72%) 240/514 (47%) 114/234 (49%) 912/1324 (69%)
MDR E. coli 453/1828 (25%) 441/1639 (27%) 2015/6956 (29%) 24/125 (19%) 24/125 (19%) 336/1204 (28%)
XDR E. coli 71/1828 (4%) 63/1639 (4%) 514/6956 (7%) 2/125 (2%) 2/125 (2%) 65/1204 (5%)
ESBL K. pneumoniae 887/1400 (63%) 555/815 (68%) 1186/2958 (40%) 91/172 (53%) 34/61 (56%) 128/365 (35%)
Imipenem K. pneumoniae 393/2 294 (17%) 259/1697 (15%) 891/3647 (24%) 64/361 (18%) 26/233 (11%) 91/454 (20%)
Ceftriaxone K. pneumoniae 1479/2 227 (66%) 626/1380 (45%) 1912/3436 (56%) 101/190 (53%) 63/175 (36%) 214/435 (49%)
MDR K. pneumoniae 318/1553 (20%) 294/1315 (22%) 428/3141 (14%) 17/112 (15%) 17/112 (15%) 53/403 (13%)
XDR K. pneumoniae 205/1553 (13%) 171/1315 (13%) 722/3141 (23%) 12/112 (11%) 12/112 (11%) 81/403 (20%)
Imipenem A. baumannii 1495/2138 (70%) 1056/1584 (67%) 2769/3551 (78%) 110/244 (45%) 85/205 (41%) 100/178 (56%)
MDR A. baumannii 897/1334 (67%) 897/1282 (70%) 2781/3442 (81%) 27/44 (61%) 27/44 (61%) 101/171 (59%)
Imipenem P. aeruginosa 578/1 765 (33%) 322/996 (32%) 1403/3220 (44%) 36/129 (28%) 22/88 (25%) 49/135 (36%)
MDR P. aeruginosa 178/576 (31%) 144/392 (37%) 660/1566 (42%) 4/25 (16%) 4/17 (24%) 17/70 (24%)
MRSA S. aureus 1 098/1 580 (69%) 950/1303 (73%) 3302/4515 (73%) 145/197 (74%) 130/171 (76%) 476/674 (71%)
Vancomycin* S. aureus 28/823 (3.4%) 10/372 (2%) 45/2680 (2%) 5/135 (3.7%) 0/65 (0%) 7/565 (1%)
Penicillin S. pneumoniae 115/344 (33%)** 115/341 (34%)** 663/1136(58%) 7/30 (23%) ** 7/30 (23%) ** 42/114 (37%)
Ceftriaxone S. pneumoniae 90/358 (25%) 31/299 (10.4%) 57/352 (16%) 9/52 (17%) 4/47 (8.5%) 17/125 (14%)
Vancomycin E. faecium 20/79 (25%) 20/79 (25%) 91/290 (31%) 2/14 (14%) 2/14 (14%) 13/51 (25%)
Ampicillin H. influenzae 160/226 (71%) 1/1 (100%) 804/911 (88%) 3/5 (60%) 1/1 (100%) 7/8 (88%)
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interest including carbapenem-resistant A. bauman-
nii, P. aeruginosa and Enterobacterales. All Chi-square 
test returned p-value < 0.0001 that highlight the differ-
ence between the two periods; except the combinations 
with only few isolates (eg. comparison of ceftriaxone-
resistant S. pneumoniae, vancomycin-resistant E. faecium 
and ampicillin-resistant H. influenzae proportions from 
blood and CSF between two periods of VINARES).
Resistant proportions for 13 pathogen-antimicrobial 
combinations of 13 hospitals that participated in both 
periods (2012–13, 2016–17) are shown in Fig.  2. Most 
hospitals had higher imipenem-resistant A. baumannii, 
K. pneumoniae, P. aeruginosa and penicillin non-suscep-
tible S. pneumoniae proportions in the second period. 
ESBL positive Enterobacterales were lower in the second 
period. No trends for vancomycin-resistant E. faecium, 
ceftriaxone-resistant Enterobacterales and MRSA were 
seen. The number of AST tests of A. baumannii, K. pneu-
moniae and E. coli remained unchanged in blood and 
CSF of 16 or 13 hospitals in VINARES 2012–2013.
The MDR proportion of E. coli, A. baumannii, P. aerug-
inosa in all specimens were higher in the second period. 
K. pneumoniae MDR went down from 22% (294/1,315 
of 13 hospitals) in first period to 14% (428/3,141) in the 
second. XDR proportions of E. coli in all specimens and 
in blood & CSF were 7% (514/6,956) and 5% (65/1,204), 
respectively. K. pneumoniae had a higher XDR than MDR 
proportion (23% (722/3,141) in second period compared 
to 14% of first period of VINARES.
Fig. 2 Resistant proportions in 2016–2017 as a function of resistance proportions in 2012–2013 for 13 pathogen-antimicrobial combinations (one 
per subplot). Each dot corresponds to one of the 13 hospitals that participated in the two VINARES periods. The line is the first diagonal, showing 
equal proportions of resistance in the 2 periods. IPM: imipenem, CRO: ceftriaxone, VAN: vancomycin, PEN: penicillin
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Discussion
We described the identification and antimicrobial sus-
ceptibility testing results from 13 laboratories within the 
VINARES network in 2016–2017. Overall, we found high 
proportions of resistance among all tested priority bac-
teria and these proportions were generally higher than 
those reported in 2012–2013.
Proportions of carbapenem-resistant Gram-negative 
pathogens increased gradually in the VINARES hos-
pitals. Carbapenem-resistant A. baumannii increased: 
40% reported from the GARP report in 2009 [11]; 70% 
(1,495/2,138) from VINARES 2012–2013 and 79% in the 
2016–2017 period. A similar observation can be made for 
carbapenem-resistant P. aeruginosa (30%, 33% and 45%, 
respectively).
In the 2012 point prevalence survey in 15 hospitals’ 
ICU in Viet Nam, Phu et al. reported that the two most 
common pathogens of hospital acquired infections (HAI) 
were A. baumannii (24%) and P. aeruginosa (14%) [9]. 
This report showed carbapenem resistance in patients 
having HAI was most common in A. baumannii (89% 
[149/167]) and P. aeruginosa (56% [49/88])[9], similar to 
our VINARES 2016 data.
In order to understand the situation in Viet Nam from 
a global perspective, we compared resistant proportions 
of VINARES 2016–2017 with national AMR surveillance 
data from LMICs which were submitted to GLASS in 
2018 and were published in the GLASS 2020 report [21]. 
Blood isolates of three countries in Asia (Laos, Cambodia 
and Myanmar) and two in Africa (Nigeria and Tunisia) 
were selected for comparison (Additional file 1:  Table 4). 
Imipenem-resistant A. baumannii in blood isolates from 
Asian countries ranged from 33% (7/21) in Cambodia to 
59% (17/29) in Myanmar [21]. In Tunisia, this resistant 
proportion was 82% (173/210), while data of Nigeria was 
not available [6]. This proportion was 60% in the VIN-
ARES data. The proportions of MRSA remained around 
70% in both data periods in VINARES, but was higher 
than reported from GARP in 2009 (from 17 to 63% in 
hospitals) [11] and from the Antimicrobial Sensitivity 
Testing Study in 2006 (42%) [22].
MRSA proportions ranged from 11% (4/35) in Laos to 
74% (117/158) in Myanmar [21] in selected Asian LMICs 
and were 66% (146/222) and 21% (102/483) in Nigeria 
and Tunisia, respectively [21]. VINARES 2016–2017 had 
similar MRSA proportions as Myanmar and Nigeria.
Vancomycin-intermediate and resistant S. aureus 
remained stable (2%) over the two time periods of VIN-
ARES with no trend observed. Vancomycin-resistance 
among S. aureus was not confirmed molecularly and we 
are unsure of the significance of these findings.
The decrease in ESBL detection among Enterobac-
terales was mostly due to changes in use of detection 
methods. This difference, looking at the denominators 
for testing between 2012 and 2016, is more likely an arte-
fact of increased ESBL testing using VITEK2 or other 
automated systems than that they signal a true decrease 
of ESBL circulation. In 2012–13 ESBL confirmation was 
only done on a proportion of ceftriaxone resistant iso-
lates in most sites, whereas in 2016–17 a number of sites 
had switched to using automated systems and almost all 
isolates were screened for ESBL production.
According to the GLASS 2020 report, ESBL car-
riage among E. coli in Asian and African countries was 
30–70%, on par with 59% from VINARES 2016–2017. 
ESBL carriage among K. pneumoniae in VINARES 2016–
2017 was 35%, lower in comparison with other countries 
(38% in Cambodia to 77% in Nigeria) [21].
An increasing trend of penicillin non-susceptible S. 
pneumoniae could not be described properly for the 
period between 2012–2013 and 2016–2017 period as 
different methods were used for assessment. There was 
a change from oxacillin disk diffusion screening in 2012 
to penicillin susceptibility test in 2016 across sites. The 
ANSORP study from 2000 to 2001 reported 91% of peni-
cillin non-susceptible S. pneumoniae [23] in Viet Nam, 
but it may not represent the true prevalence of the entire 
country because samples were taken in only one hospital 
in Ho Chi Minh city.
Results from the SOAR study (2009–2011) in 11 cen-
tres in Viet Nam reported that 51% (100/195) of H. influ-
enzae were resistant to ampicillin [24]. In the VINARES 
2016–17 data, ampicillin resistant proportions increased 
further from 71% in 2012–2013 to 88% in 2016–2017.
Despite the number of hospitals participating in the 
surveillance network being lower in the second period, 
the number of isolates submitted was significantly higher. 
Proportions of AMR were also higher for a number of 
bug-drug combinations, reflecting the possibly true 
increases in resistance] over time, the increasing labo-
ratory capacity and the increasing use of microbiology 
testing as part of diagnostic and antibiotic stewardship 
programmes. We found a decrease of K. pneumoniae 
MDR in VINARES 2016–2017. This decrease might not 
reflect an actual trend, but could be explained by the defi-
nition of MDR as a K. pneumoniae MDR isolate is sus-
ceptible to carbapenems by definition and. carbapenem 
resistance increased.
Our results document a higher proportion of resist-
ance in national than in provincial level hospitals. Pre-
vious studies [25–27] have shown that the proportion 
of patients with hospital-acquired infection is higher in 
national hospitals. As bacteria associated with hospi-
tal acquired infections are usually more resistant, this 
may partially explain our observation. Furthermore, 
in accordance with national health recommendations, 
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patients with resistant bacterial infections or patients 
unresponsive to therapy because of resistance are gen-
erally transferred from provincial to national level hos-
pitals, which could further explain the higher levels of 
resistance in national level hospitals.
Limitations
VINARES collected isolate-based data (surveillance 
approaches based solely on laboratory data), without 
epidemiological, clinical, and population-level data. Cur-
rently, GLASS accepts both isolate-based and sample-
based data, but it encourages countries to collect and 
report sample-based data, which can provide strati-
fied and therefore more useful information [6]. Current 
data collected in VINARES do not allow to differenti-
ate between hospital or community acquired infections. 
Therefore, resistant proportions may be inflated when 
trying to use data to inform empiric treatment for com-
munity acquired infections. Sample- or case-based data 
collection may provide potential solutions for this issue.
AST data were collected from isolates cultured from 
samples sent in for routine diagnostics as part of stand-
ard of care. While our study did not make any selection 
of samples and included all laboratory results, it is known 
that microbiology is underused in many LMICs for vari-
ous reasons [28] which may lead to bias, usually towards 
overestimating resistant proportions.
A standardized sampling and data collection strategy 
across the whole surveillance network is important to 
minimize sampling biases, enhance representativeness 
and interpretation of the results, and allow inference of 
the results to the country representativeness [6]. The 
change in the participation of hospitals had impact on 
the overall resistant proportions.
Conclusions
We show the results from a successful continuation of 
a large AMR surveillance network in Viet Nam. The data 
show alarmingly high and increasing resistant proportions 
in important organisms causing infections in Viet Nam. 
However, AMR proportions varied across hospital types 
in the network. The results may not reflect the true AMR 
prevalence in Viet Nam as there may be sampling biases 
and data on whether isolates were from hospital- or com-
munity-acquired were not included. Affordable and scal-
able ways to adopt a sample-or case-based approach across 
the network should be explored. Clinical data should also 
be included in the reports from the hospitals to help pro-
vide more informative interpretations of the surveillance 
data.
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